Lancet, 394(10212), 1940-1948. Elsevier Limited VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8 Lancet The Lancet, 394(10212), 1940. Elsevier Limited
lancet. Respiratory medicine, 9(7), 733-746. Elsevier Limited VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5